Stay updated on Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Adds sponsor/collaborator institutions—Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine—and a new 'Helpful Links Provided by' section.
    Difference
    0.6%
    Check dated 2025-11-03T21:22:14.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The affiliations for Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, and for Washington University School of Medicine, have been removed. The 'Helpful Links Provided by' section is no longer displayed.
    Difference
    0.2%
    Check dated 2025-10-27T20:39:38.000Z thumbnail image
  3. Check
    34 days ago
    Change Detected
    Summary
    - Added a government-funding notice about potential delays and updated operating status guidance, and a major version bump to v3.2.0. - Removed the previous version tag v3.1.0.
    Difference
    3%
    Check dated 2025-10-06T05:55:37.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    Removed a specific resource entry for a disease and updated the page version to v3.1.0.
    Difference
    0.5%
    Check dated 2025-09-29T03:13:27.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    Revision updated to v3.0.2 and Back to Top removed; no core content or critical information is affected.
    Difference
    0.2%
    Check dated 2025-09-14T20:13:20.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1.
    Difference
    0.2%
    Check dated 2025-09-07T17:06:35.000Z thumbnail image

Stay in the know with updates to Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.